SG Americas Securities LLC grew its stake in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 167.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,612 shares of the biotechnology company's stock after purchasing an additional 23,525 shares during the quarter. SG Americas Securities LLC owned approximately 0.07% of Prothena worth $521,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also modified their holdings of the company. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Prothena in the 4th quarter valued at about $724,000. Barclays PLC lifted its stake in Prothena by 110.2% in the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company's stock valued at $1,592,000 after buying an additional 49,916 shares during the last quarter. Orion Portfolio Solutions LLC boosted its holdings in shares of Prothena by 4.4% in the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock valued at $293,000 after acquiring an additional 739 shares during the period. XTX Topco Ltd purchased a new position in shares of Prothena during the third quarter worth approximately $260,000. Finally, Wellington Management Group LLP increased its holdings in shares of Prothena by 14.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company's stock valued at $69,911,000 after acquiring an additional 539,359 shares during the period. Hedge funds and other institutional investors own 97.08% of the company's stock.
Prothena Price Performance
Shares of PRTA stock traded up $1.05 during trading hours on Tuesday, reaching $14.49. 513,463 shares of the company's stock were exchanged, compared to its average volume of 401,480. Prothena Co. plc has a 1 year low of $11.70 and a 1 year high of $31.03. The company has a market cap of $779.71 million, a P/E ratio of -5.84 and a beta of 0.08. The company's 50 day moving average is $14.37 and its two-hundred day moving average is $17.52.
Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The firm had revenue of $0.97 million during the quarter, compared to analysts' expectations of $1.22 million. During the same quarter in the prior year, the business posted $0.38 earnings per share. Prothena's revenue was down 98.9% compared to the same quarter last year. As a group, analysts predict that Prothena Co. plc will post -2.24 EPS for the current fiscal year.
Analyst Ratings Changes
PRTA has been the subject of a number of recent research reports. Chardan Capital initiated coverage on shares of Prothena in a research note on Friday, December 20th. They set a "buy" rating and a $40.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $48.00 target price (down previously from $84.00) on shares of Prothena in a research note on Friday, December 20th. StockNews.com cut Prothena from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th. Finally, Bank of America decreased their price objective on Prothena from $26.00 to $22.00 and set a "neutral" rating for the company in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Prothena has a consensus rating of "Moderate Buy" and a consensus price target of $46.50.
Check Out Our Latest Analysis on PRTA
About Prothena
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
